193. プラダー・ウィリ症候群
[臨床試験数:95,薬物数:104(DrugBank:27),標的遺伝子数:50,標的パスウェイ数:63

Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04283578
(ClinicalTrials.gov)
March 10, 202019/2/2020Oxytocin Treatment in Neonates and Infants With Prader-Willi SyndromeOxytocin Treatment in Neonates and Infants Aged From 0 to 3 Months With Prader-Willi Syndrome : a Study of Safety and Efficacy on Oral and Social Skills and Feeding Behavior of Intranasal Administration of Oxytocin vs PlaceboPrader-Willi SyndromeDrug: OT;Drug: Placebo comparatorUniversity Hospital, ToulouseInternational Clinical Trials Association;Epidemiological and Clinical Research Information NetworkRecruitingN/A92 DaysAll48Phase 3France
2NCT04066088
(ClinicalTrials.gov)
December 1, 201921/8/2019Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi SyndromeDose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi SyndromePrader-Willi SyndromeOther: Placebo;Drug: Guanfacine extended release (GXR)NYU Langone HealthWinthrop University HospitalWithdrawn6 Years35 YearsAll0Phase 4United States
3EUCTR2019-002385-12-FR
(EUCTR)
27/08/201912/06/2019OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROMEOXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND, FEEDING BEHAVIOR OF INTRANASAL ADMINISTRATIONS OF OXYTOCIN VS. PLACEBO (PHASE III CLINICAL TRIAL) - OTBB3 Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19]University Hospital of ToulouseNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
48Phase 3France
4NCT03081832
(ClinicalTrials.gov)
January 201710/3/2017Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.Long Term Evaluation of Infants Aged From 3 to 4 Years Old Included in the Ancient Study (Repeated Administrations of Oxytocin in Infants With Prader Willi Syndrome Aged From 0 to 6 Months) and Comparison With Not Treated and Age-matched Prader Willi Syndrome Infants (OT2SUITE)Prader-Willi SyndromeDrug: Oxytocin;Other: ControlUniversity Hospital, ToulouseNULLCompleted3 Years4 YearsAll34N/AFrance
5NCT02368379
(ClinicalTrials.gov)
March 20145/2/2015Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi SyndromeDiagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi SyndromePrader Willi Syndrome;Adrenal InsufficiencyOther: Low dose (1 mcg) ACTH stimulation test;Other: Overnight metyrapone testNationwide Children's HospitalNULLCompleted2 YearsN/AAll23N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01548521
(ClinicalTrials.gov)
July 201130/12/2011Tolerance of Intranasal Administration of OT in Prader-Willi Newborn BabiesTolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies and Effect on Suck and Food Intake.Prader-Willi SyndromeDrug: OxytocinUniversity Hospital, ToulouseNULLCompletedN/A5 MonthsAll5Phase 1;Phase 2France
7EUCTR2019-002385-12-BE
(EUCTR)
06/03/2020OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROMEOXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND, FEEDING BEHAVIOR OF INTRANASAL ADMINISTRATIONS OF OXYTOCIN VS. PLACEBO (PHASE III CLINICAL TRIAL) - OTBB3 Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Product Name: Oxytocin
INN or Proposed INN: OXYTOCIN
Other descriptive name: OXYTOCIN
University Hospital of ToulouseNULLNAFemale: yes
Male: yes
48Phase 3France;Belgium
8EUCTR2019-002385-12-NL
(EUCTR)
08/09/2020Oxytocin treatment in neonates and infants aged from 0 to 3 months with prader-willi syndromeOxytocin treatment in neonates and infants aged from 0 to 3 months with prader-willi syndrome: a study of the safety and efficacy on oral and social skills and, feeding behavior of intranasal administrations of oxytocin vs. placebo (phase iii clinical trial) - OTBB3 Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Product Name: Oxytocin
INN or Proposed INN: OXYTOCIN
Other descriptive name: OXYTOCIN
University Hospital of ToulouseNULLNAFemale: yes
Male: yes
48Phase 3France;Belgium;Netherlands
9EUCTR2010-022370-14-FR
(EUCTR)
15/11/2010Evaluation de la tolérance d'une administration intra-nasale d'ocytocine chez des nourrissons présentant un syndrome de Prader-Willi et de son effet sur la succion et la prise alimentaire. - OTBBEvaluation de la tolérance d'une administration intra-nasale d'ocytocine chez des nourrissons présentant un syndrome de Prader-Willi et de son effet sur la succion et la prise alimentaire. - OTBB Syndrome de Prader Willi
MedDRA version: 12.1;Level: LLT;Classification code 10036476;Term: Prader-Willi syndrome
Trade Name: SyntocinonCentre Hospitalier de ToulouseNULLNAFemale: yes
Male: yes
Phase 2France